Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381787 | 0.81 | — | — | |
| SCHEMBL5913713 | 0.77 | ALDH1A1 (0.32) | TP53 | |
| SCHEMBL28371972 | 0.75 | ALDH1A1 (0.31) | TP53 | |
| SCHEMBL21155856 | 0.72 | CYP1A2 (0.48) | — | |
| SCHEMBL1234589 | 0.71 | SLC22A6 (0.33) | — | |
| Water SCHEMBL30441965 | 0.71 | SCN1A (0.34) | TP53 | |
| SCHEMBL3381816 | 0.70 | — | — | |
| SCHEMBL11963160 | 0.70 | — | — | |
| SCHEMBL7617404 | 0.70 | TP53 (0.32) | TP53 | |
| SCHEMBL30173247 | 0.70 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| EP-2531026-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | claimed |
| US-20120282351-A1 | System and Method for The Prevention of Bacterial and Fungal Infections Including Urinary Tract Infections (UTI) Using N-Halogenated Amino Acids | NOVABAY PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | claimed |
| WO-2011097324-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | claimed |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | NOVABAY PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| US-7893109-B2 | N,N-dihalogenated amino acids and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | claimed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| EP-1948154-A1 | SYSTEM AND METHOD FOR THE PREVENTION OF BACTERIAL AND FUNGAL INFECTIONS INCLUDING URINARY TRACT INFECTIONS (UTI) USING N-HALOGENATED AMINO ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1656095-A4 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES | NOVACAL PHARMACEUTICALS INC (US) | 2007-11-28 | — | — | EP | claimed |
| US-20070244449-A1 | System and method for the prevention of bacterial and fungal infections including Urinary Tract Infections (UTI) using N-halogenated amino acids | NOVACAL PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | claimed |
| WO-2007044559-A1 | SYSTEM AND METHOD FOR THE PREVENTION OF BACTERIAL AND FUNGAL INFECTIONS INCLUDING URINARY TRACT INFECTIONS (UTI) USING N-HALOGENATED AMINO ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | claimed |
| EP-1656095-A2 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES | NovaCal Pharmaceuticals, Inc. (US) | 2006-05-17 | — | — | EP | claimed |
| US-20050065115-A1 | N,N-dihalogenated amino acids and derivatives | NOVABAY PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2005020896-A2 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES | NOVACAL PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | TP53 1117/4885CA12 3048/4885CA1 4102/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | TP53 1647/4885CA12 4659/4885CA1 4807/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | TP53 3000/4885CA12 3693/4885CA1 4304/4885 |
| US-20050065115-A1 | N,N-dihalogenated amino acids and derivatives | DAO, DDC, NRDC | TP53 1177/4885CA12 4770/4885CA1 4651/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | TP53 1647/4885CA12 4659/4885CA1 4807/4885 |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | DAO, ASNS, DDC | TP53 998/4885CA12 4591/4885CA1 3944/4885 |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | FUT6, FUT5, OGT | TP53 3338/4885CA12 2688/4885CA1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.